Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryan A Lafferty

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Current Opinion in Endocrinology, Diabetes, and Obesity|January 4, 2021
Established and emerging roles peptide YY (PYY) and exploitation in obesity-diabetesRyan A Lafferty, Peter R Flatt, Nigel Irwin
Peptides|June 2, 2024
NPYR modulation: Potential for the next major advance in obesity and type 2 diabetes management?Ryan A Lafferty, Peter R Flatt, Nigel Irwin
Expert Opinion on Pharmacotherapy|March 17, 2023
GLP-1/GIP analogs: potential impact in the landscape of obesity pharmacotherapyRyan A Lafferty, Peter R Flatt, Nigel Irwin
Peptides|February 8, 2018
Emerging therapeutic potential for peptide YY for obesity-diabetesRyan A Lafferty, Peter R Flatt, Nigel Irwin
Biochimica Et Biophysica Acta. General Subjects|February 3, 2020
Development and characterisation of a peptidergic N-and C-terminally stabilised mammalian NPY1R agonist which protects against diabetes inductionRyan A Lafferty, Neil Tanday, Peter R Flatt, et al.
Diabetes, Obesity & Metabolism|July 18, 2022
Beneficial metabolic effects of recurrent periods of beta-cell rest and stimulation using stable neuropeptide Y1 and glucagon-like peptide-1 receptor agonistsNeil Tanday, Ryan A Lafferty, Peter R Flatt, et al.
Metabolism: Clinical and Experimental|August 11, 2020
Generation and characterisation of C-terminally stabilised PYY molecules with potential in vivo NPYR2 activityRyan A Lafferty, Neil Tanday, Peter R Flatt, et al.
Clinical Medicine Insights. Endocrinology and Diabetes|June 28, 2019
Effects of 2 Novel PYY(1-36) Analogues, (P<sup>3</sup>L<sup>31</sup>P<sup>34</sup>)PYY(1-36) and PYY(1-36)(Lys<sup>12</sup>PAL), on Pancreatic Beta-Cell Function, Growth, and SurvivalRyan A Lafferty, Victor A Gault, Peter R Flatt, et al.
Chemosphere|June 30, 2015
Galleria mellonella as a novel in vivo model for assessment of the toxicity of 1-alkyl-3-methylimidazolium chloride ionic liquidsJulianne Megaw, Thomas P Thompson, Ryan A Lafferty, et al.
The Journal of Endocrinology|June 11, 2024
Does glucose-dependent insulinotropic polypeptide receptor blockade as well as agonism have a role to play in management of obesity and diabetes?Ryan A Lafferty, Peter R Flatt, Victor A Gault, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Current Opinion in Endocrinology, Diabetes, and Obesity|January 4, 2021
Established and emerging roles peptide YY (PYY) and exploitation in obesity-diabetesRyan A Lafferty, Peter R Flatt, Nigel Irwin
Peptides|June 2, 2024
NPYR modulation: Potential for the next major advance in obesity and type 2 diabetes management?Ryan A Lafferty, Peter R Flatt, Nigel Irwin
Expert Opinion on Pharmacotherapy|March 17, 2023
GLP-1/GIP analogs: potential impact in the landscape of obesity pharmacotherapyRyan A Lafferty, Peter R Flatt, Nigel Irwin
Peptides|February 8, 2018
Emerging therapeutic potential for peptide YY for obesity-diabetesRyan A Lafferty, Peter R Flatt, Nigel Irwin
Biochimica Et Biophysica Acta. General Subjects|February 3, 2020
Development and characterisation of a peptidergic N-and C-terminally stabilised mammalian NPY1R agonist which protects against diabetes inductionRyan A Lafferty, Neil Tanday, Peter R Flatt, et al.
Diabetes, Obesity & Metabolism|July 18, 2022
Beneficial metabolic effects of recurrent periods of beta-cell rest and stimulation using stable neuropeptide Y1 and glucagon-like peptide-1 receptor agonistsNeil Tanday, Ryan A Lafferty, Peter R Flatt, et al.
Metabolism: Clinical and Experimental|August 11, 2020
Generation and characterisation of C-terminally stabilised PYY molecules with potential in vivo NPYR2 activityRyan A Lafferty, Neil Tanday, Peter R Flatt, et al.
Clinical Medicine Insights. Endocrinology and Diabetes|June 28, 2019
Effects of 2 Novel PYY(1-36) Analogues, (P<sup>3</sup>L<sup>31</sup>P<sup>34</sup>)PYY(1-36) and PYY(1-36)(Lys<sup>12</sup>PAL), on Pancreatic Beta-Cell Function, Growth, and SurvivalRyan A Lafferty, Victor A Gault, Peter R Flatt, et al.
Chemosphere|June 30, 2015
Galleria mellonella as a novel in vivo model for assessment of the toxicity of 1-alkyl-3-methylimidazolium chloride ionic liquidsJulianne Megaw, Thomas P Thompson, Ryan A Lafferty, et al.
The Journal of Endocrinology|June 11, 2024
Does glucose-dependent insulinotropic polypeptide receptor blockade as well as agonism have a role to play in management of obesity and diabetes?Ryan A Lafferty, Peter R Flatt, Victor A Gault, et al.
Pageof 3